Blood Transfusion Management in Polycythemia Vera Patients

Understanding Polycythemia Vera and Transfusion Considerations

Polycythemia vera is characterized by excessive red blood cell production, leading to increased blood viscosity and thrombotic risk, according to the American Society of Clinical Oncology 1
The primary treatment goal is to reduce hematocrit below 45% through phlebotomy and cytoreductive therapy to prevent thrombotic complications, as recommended by the European Society for Medical Oncology 2
Transfusions are counterintuitive to this goal as they would further increase red cell mass and exacerbate hyperviscosity, as noted by the Mayo Clinic 3

Transfusions should only be considered in PV patients with perioperative blood loss requiring immediate replacement, as suggested by the American College of Surgeons 2
Transfusions may be necessary in cases of development of secondary bone marrow failure or transformation to myelofibrosis with cytopenias, according to the American Society of Hematology 1

When transfusion is absolutely necessary, leukoreduced blood products should be used to minimize inflammatory reactions, as recommended by the American Association of Blood Banks 2
Small-volume transfusions with careful monitoring of hematocrit levels should be considered, as noted by the Mayo Clinic 3
Therapeutic phlebotomy should be performed before transfusion if the clinical situation allows, to maintain hematocrit below 45%, as suggested by the European Hematology Association 2

Low-dose aspirin therapy should be continued during the perioperative period to reduce thrombotic risk, as recommended by the American Heart Association 2

Platelet transfusions should be avoided in PV patients with thrombocytosis, as suggested by the American Society of Hematology 2
PV patients may have qualitative platelet defects that can contribute to bleeding risk despite normal or elevated platelet counts, as noted by the Mayo Clinic 3

Hematocrit levels should be closely monitored before, during, and after transfusion, as recommended by the European Society for Medical Oncology 2
Signs of volume overload should be watched for, which may be exacerbated by increased blood viscosity, as noted by the American College of Cardiology 4

Routine transfusions that would counteract the therapeutic goal of maintaining hematocrit <45% should be avoided, as suggested by the European Hematology Association 2
Higher hemoglobin thresholds for transfusion should be applied in PV patients, as recommended by the American Society of Clinical Oncology 4